A5075591565- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Low-power high-performance VLSI design
- Integrated Circuits and Semiconductor Failure Analysis
Research Institute in Oncology and Hematology
2020-2021
CancerCare Manitoba
2020-2021
University of Manitoba
2017-2021
Health Sciences Centre
2021
PTEN mutation occurs in a variety of aggressive cancers and is associated with poor patient outcomes. Recent studies have linked mutational loss to reduced RAD51 expression function, key factor involved the homologous recombination (HR) pathway. However, these remain controversial, as they fail establish definitive causal link that PTEN-dependent, while other not been able recapitulate relationship between RAD51/HR function. Resolution this apparent conundrum essential due...
Abstract Introduction: Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with poor treatment outcomes and prognoses. Treatment usually consists surgery, radiation chemotherapy, which often result in severe systemic side effects frequently accompanied by tumor recurrence highly radioresistant cell populations. PARP-1 a nuclear enzyme crucial for DNA damage repair (DDR) response. inhibition studied adjuvant to many anti-cancer strategies as this arrests thus enhancing the...